The European Research Council (ERC) has awarded Associate Professor Jakub Sedzinski, from the Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW Copenhagen node, and his team, a two million euro grant for their work on understanding how mechanical forces regulate embryo development.
Bringing together research excellence to harness the therapeutic potential in stem cell medicine
Professor and CEO
reNEW – a unique global research center in stem cell medicine
reNEW is an international consortium of three leading research institutions in Denmark, Australia and the Netherlands, led by renowned Professor and CEO Melissa Little. We strive to advance a new generation of effective and safe stem cell-based therapies, built on a global collaborative network of excellence in targeted biomedical research.
Translating research into new stem cell medicine
The aim of the center is to strengthen the pathway from stem cell discovery research to clinical outcomes. We will apply our understanding of stem cells to improve drug development and deliver novel cell and tissue therapies.
Understanding stem cells and how they can be used
A stem cell can renew itself and generate other cell types. We all rely on stem cells to exist and to survive. Understanding stem cells and their potential has long been of interest to researchers across the globe. Stem cell medicine refers to the application of that understanding to accelerate the development of new therapies for people living with incurable diseases.
Be part of transformative science
Join us in delivering the next generation of effective and safe stem cell-based therapies. reNEW is situated in three places – Copenhagen, Leiden and Melbourne. But no matter where in the world you are, you can help us transform the future of stem cell medicine.
Impacting the world with our science
Find out the latest in the world of stem cell medicine.
Researchers from the lab of reNEW PI Ton Rabelink have discovered in collaboration with Arnaud Zaldumbide (LUMC) that knockout of HLA class 1 by itself is insufficient to protect transplanted kidney organoids from T-cell mediated rejection.
Diabetes, affecting 537 million people globally and the number being projected to rise to 783 million by 2045, demands innovative solutions.